Microglial phenotypes in Parkinson's disease and animal models of the disease

Valerie Joers1, Malú G Tansey2, Giovanna Mulas3

  • 1Department of Physiology, Emory University, Atlanta, GA, United States; Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.

Insights

Microglia, immune cells in the brain, exhibit diverse phenotypes in Parkinson's disease (PD). Understanding these dynamic changes and their role in neuroinflammation is crucial for developing effective PD treatments.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Microglia, the brain's resident immune cells, are increasingly recognized for their diverse phenotypes and functions, analogous to tissue macrophages.
  • In Parkinson's disease (PD), neuroinflammation and microglial activation are key pathological features, but their exact role in disease progression remains unclear.

Purpose of the Study:

  • To critically review current knowledge on microglial activation states and phenotypes in Parkinson's disease (PD) and relevant animal models.
  • To focus on surface molecule expression and cytokine production by microglia during PD pathogenesis.
  • To explore the potential link between NFκB signaling dysfunction and pathological microglial activation in PD.

Main Methods:

  • Review of existing literature on microglial phenotypes in PD.
  • Analysis of studies examining surface markers and cytokine profiles in human PD patients and animal models.
  • Examination of evidence regarding NFκB signaling pathways in PD-related microglial activation.

Main Results:

  • Microglia exhibit a continuum of phenotypes, not just polarized states, influenced by the local microenvironment.
  • Human studies show elevated pro- or anti-inflammatory markers in PD patients' serum and CSF.
  • Animal models reveal dynamic microglial phenotype changes preceding motor deficits in PD, with potential NFκB signaling involvement.

Conclusions:

  • Microglial activation is a complex, dynamic process in PD, with phenotypes existing along a spectrum.
  • Further research into microglial phenotypes and signaling pathways is essential for developing targeted, disease-modifying therapies for PD.
  • Immune-modifying strategies targeting chronic microglial activation represent a promising therapeutic avenue for PD.